Atypia and malignancy aside, the most important factor in predicting meningioma recurrence is completeness of resection: 10-year recurrence rates vary from 10% for tumors determined macroscopically to be totally excised (including dural attachment and any abnormal bone) to 100% for tumors that have simply been debulked. 52 The site is considered relevant because the least accessible tumors and those intimately related to vital structures are less likely to be totally resected. 10 The histological subtype of benign meningiomas is not related to risk of recurrence. 33 The higher incidence of meningiomas in women (female/male preponderance 2:1), 48 the observation that in women these tumors may enlarge and become symptomatic during hormonal flux, particularly during pregnancy 40 and in the luteal phase of the menstrual cycle, 5 and the observation of a nonrandom association between meningioma and carcinoma of the breast 51 indicate that female hormones play a role in the growth of meningiomas. Although estrogen receptor levels in these tumors are variable and usually undetectable, PRs are found in most meningiomas (50-88%). 7, 9, 16, 17, 19, 20, 22 The PRs are functional and therefore may play an important role in meningioma growth. 13, 41 In recent studies investigators have found associations between PR status and factors related to meningioma growth/recurrence. On the Ki-67 assay, 56 absence of PRs has been shown to be associated with a high cellular proliferative index, high mitotic index, 21 and high tumor grade/nonbenign tumors. 8, 17, 21 Hsu, et al., 21 have recently demonstrated that absence of PRs, high mitotic index, and higher tumor grade are significant factors for shorter disease-free intervals following surgery. There is little information in the literature regarding the prognostic significance of PR status and meningioma recurrence in benign tumors only, which is the group in which most recurrences will manifest. Between 1983 and 1985, meningiomas treated in our department were studied in detail. Clinical, histological, and various pathological characteristics were assessed, including hormone receptor status and DNA features. 22, 23, 38 On the basis of these studies we thought that hormone receptor status and cellular proliferative index might be involved in the biological progression of the tumors. We therefore proposed a prospective analysis of factors affecting recurrence.
Clinical Material and Methods
Between 1983 and 1985, a total of 53 patients harboring 62 tumors presented to the Royal Hallamshire Hospital, Sheffield and underwent surgery for meningioma. The patients came from a reporting area with a population of 2.2 million relevant to our unit. Thirty-seven patients (70%) were women and 16 (30%) were men, with an age range of 19 to 79 years (mean 55.6 years). Age, sex, and clinical presentation were recorded. The site of origin of each tumor was identified on radiological studies and confirmed at the time of surgery. Complete excision correlated to Simpson Grade I and incomplete to Simpson Grades II to V. 52 The histological subtype of each tumor conformed to the World Health Organization classification (1979), 57 and at the time of analysis (1997) the subtype conformed to the World Health Organization classification of tumors of the meninges (1993). 27 The PR status of each tumor was quantified by cryostat section assay. 22 This method was chosen because at the assay levels accepted as significant, it is thought to be as reliable as and less subjective than the assessment of cells in immunohistochemical preparations. Having quantified PR levels, analysis of the results may indicate a level suitable for a predictive value. Progesterone receptor levels exceeding 10 fmol/mg of cytosol protein were considered PR positive. Postoperatively all patients underwent follow-up evaluation at regular intervals on an outpatient basis. During 1997 the case records of all patients were scrutinized to determine whether tumor had recurred; recurrence and nonrecurrence were confirmed radiologically. The clinicopathological features of the nonrecurrent and recurrent tumors were compared. Forty-six of 62 tumors were included in the final analysis. Of the tumors excluded, two were malignant, follow up for more than 5 years was not available in 10, and patients with a total of four tumors had died.
Results
Sixty benign neoplasms were studied, of which 29 (48%) were PR positive. Nineteen tumors (32%) occurred in men, of which eight (42%) were PR positive, and 41 (68%) occurred in women, of which 21 (51%) were PR positive. Fourteen of these tumors were not included in the final analysis. Of the 46 tumors included in the final analysis, 14 (30%) occurred in men, of which five (36%) were PR positive, and 32 (70%) occurred in women, of which 13 (41%) were PR positive. Twenty-eight tumors were PR negative. Twenty tumors were estimated to have been completely excised and 26 were incompletely excised.
Thirteen of the 46 tumors were recurrent: seven were postsurgical recurrences during the period studied (all within 5 years of surgery), and six had been recurrent tumors at the time of initial surgery between 1983 and 1985 (in all cases the first surgery for the tumor was Ͻ 5 years previously). For patients with nonrecurrent lesions, follow-up periods of between 5 and 10 years (14 tumors) and more than 10 years (19 tumors) were reported.
In Table 1 we compare tumor recurrence with PR status and show that benign meningiomas that were PR positive were less likely to recur (p = 0.013). Tumor recurrence was also related to the patient's sex, extent of resection (Table 1) , and histological findings and tumor site ( Table  2) ; none of these variables were statistically significant.
There were no major differences with regard to patient age or sex, tumor PR status, extent of resection, histological subtype, or in the tumors excluded from final analysis compared with the 46 lesions studied. We have assumed therefore that the exclusion criteria have not introduced any bias into the final analysis.
Discussion
In this study we demonstrate the previously observed lack of association between PR status and sex 6, 20, 22, 35 but do not show an association between patient's sex and tumor recurrence as has been reported by others. 8, 32 This can perhaps be explained by the fact that in our study we only investigated recurrences of benign meningiomas and that the sample included only a few young men (Ͻ 40 years old; seven individuals). Regarding sex and recurrence, the previously demonstrated association is between young men and atypical/malignant meningiomas.
We did not find a significant association between tumor site and recurrence, although there was a trend for basal tumors to recur, in keeping with previous studies. 10 Our results did not show a significant difference for recurrence rate and extent of resection, although a trend was demonstrated. The majority of the incomplete resection group were classified as Simpson Grade II, 52 the 10-year recurrence rate being 15%. The 10-year recurrence rate for Simpson Grade I resections (total resection with dural attachment) is 10%. 52 Because most of the tumors in our study were either completely or significantly resected, this may explain our findings. No association was shown between tumor resection and a benign histological subtype, which agrees with previous reports. 26, 33 Although we have shown that PR-positive meningiomas were less likely to recur, review of the quantitative data ( Fig. 1 ) reveals that at PR levels of less than 10 fmol/ mg of cytosol protein (the level at which appreciable levels of PR were accepted: "PR positive"), the sensitivity and specificity of the PR levels as a predictor of recurrence is only 85% and 45%, respectively. Our results indicate that PR negativity is associated with an increased risk of recurrence of benign meningiomas. Previous investigators have shown an increased rate of recurrence in association with PR negativity, high mitotic rate, and higher tumor grade, 21 and others have demonstrated that PR negativity is associated with a high cellular proliferative index, 56 high mitotic index, 21 and nonbenign tumors. 8 Also, the presence of PRs has been shown to result in a more favorable prognosis in patients with breast cancer. 14, 45 The mechanism by which PR positivity carries a more favorable prognosis remains unclear. In all series in which the relationship between PR status and recurrence has been investigated, recurrences have been shown in the PR-positive group, which indicates that other factors are involved. In several series, the presence of other hormone receptors in meningioma tissue has been identified, including androgen, 12 glucocorticoid, 13 somatostatin, 47 and dopamine, 11 although none has been associated with recurrence. Growth factors shown to stimulate meningioma include platelet-derived growth factor, 2,37 insulin-like growth factor-I and -II 3 (also shown to be associated with anaplasia in meningioma), 42 epidermal growth factor, and fibroblast growth factor. 1, 47, 55 Although the mechanism of action of growth factors has not been elucidated, intracellular calcium appears to be part of the signal transduction mechanism. Voltage-dependent calcium channel blocking agents have been shown to cause a dose-response decrease in meningioma cell growth in vitro. 25 The mechanism by which PR positivity results in a more favorable prognosis may be mediated by angiogenesis inhibition. Angiogenesis is known to play an impor-
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Long-term follow up of PR status in benign meningioma tant role in tumorigenicity. Plasminogen activator inhibitor Type 1, which is present in proliferating blood vessels, is more strongly expressed in malignant meningiomas than in benign meningiomas. 28 The authors of a recent study have shown that the activity of thrombospondin-1, an inhibitor of angiogenesis, is enhanced by progesterone and suppressed by the antiprogesterone agent RU-486; the release of thrombospondin-1 in the human endometrium is regulated by progesterone. 24 The observation of functional PRs in meningioma has led to several studies investigating hormone manipulation and antiprogesterone agents as possible therapeutic agents. Both in vitro 34, 36, 43 and in vivo 36, 44 studies have been conducted in which differing efficacies of antiprogesterone agents were shown. For example, RU-486 has been shown to reduce meningioma growth in vitro (meningioma cell culture) and in vivo (meningioma transplanted into nude mice). This beneficial effect has not been consistent when RU-486 has been used to treat meningiomas in humans; however, in one study control of tumor growth has been demonstrated in six of 10 patients who had shown recent evidence of such growth. In three of those six, consistent tumor shrinkage was observed. 30 A study has also been conducted in humans to investigate the efficacy of gestrinone, a synthetic antiprogesterone agent, in controlling growth of known active tumors; there were beneficial results for some patients. 15 It seems paradoxical that antiprogesterone agents should be beneficial in controlling growth/recurrence of meningiomas when it has been demonstrated that increased growth/recurrence is associated with PR negativity. Matsuda, et al., 36 confirmed the antitumor effect of RU-486 and a newer potent antiprogesterone, onapristone, on meningiomas, both in vitro and in vivo, and the antitumor effect occurred regardless of the tumor's PR status, indicating that the antitumor effect is manifested via the PRs and/or another receptor.
Conclusions
In previous studies an association has been demonstrated between PR status and high mitotic index, tumor grade, and recurrence. In this study we demonstrate that PR negativity is associated with recurrence of benign meningiomas. There is now substantive evidence of the importance of PR status with regard to meningioma recurrence. However, PR status alone is not specific enough to rationalize expending clinical resources for follow up or to aid accurate prognosis. The wide availability of monoclonal antibodies to the PR 18, 46 will facilitate further research in this field. The relationship of PR status and other hormone receptors/growth factors to meningioma recurrence merits further study and may have important prognostic and therapeutic implications.
